Literature DB >> 15798675

Low prevalence of antibodies to human T-lymphotropic virus-I/II among blood donors in eastern Saudi Arabia.

Naglaa A Fawaz1, Hala Tamim, Wassim Y Almawi.   

Abstract

The seroprevalence of human T-lymphotropic virus (HTLV)-I/II was assessed in 13,443 consecutive blood donors in eastern Saudi Arabia between 1998 and 2001. Screening by enzyme-linked immunosorbent assay (ELISA) and confirmation by Western blot resulted in 8 (0.060%) positive cases, of which 5 (0.056%) belonged to Saudi and 3 (0.113%) to non-Saudi donors. The majority of the HTLV-positive donations (6/8) were for patients, and none had a history of known risk factor for HTLV-I/II transmission. Although the very low prevalence of HTLV-I/II among Saudi donors does not support routine screening, screening of donors from other nationalities may be initiated, especially those from HTLV-I/II endemic areas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15798675     DOI: 10.1016/j.ajic.2004.08.006

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  3 in total

Review 1.  Updates on the Epidemiology of the Human T-Cell Leukemia Virus Type 1 Infection in the Countries of the Eastern Mediterranean Regional Office of the World Health Organization with Special Emphasis on the Situation in Iran.

Authors:  Mohammad Reza Hedayati-Moghaddam; Reza Jafarzadeh Esfehani; Hiba El Hajj; Ali Bazarbachi
Journal:  Viruses       Date:  2022-03-23       Impact factor: 5.818

2.  Trends in the seroprevalence of HTLV-1 in Japanese blood donors in Nagasaki Prefecture, 2000-2006.

Authors:  Masako Iwanaga; Shin Chiyoda; Eisuke Kusaba; Shimeru Kamihira
Journal:  Int J Hematol       Date:  2009-06-23       Impact factor: 2.490

Review 3.  A Systematic Review for Estimation of HTLV-I Infection in the Blood Donors of Iran.

Authors:  Mohammad Reza Hedayati-Moghaddam
Journal:  Iran J Basic Med Sci       Date:  2013-03       Impact factor: 2.699

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.